Xeris Biopharma jumps on news of Amgen deal

12 January 2024
xeris_pharmaceuticals_big

Shares of USA-based was Xeris Biopharma (Nasdaq: XERS) were up 12% to $2.67 in morning trading yesterday, after it announced a licensing deal with biotech major Amgen (Nasdaq: AMGN). The shares have more than doubled in the last year.

Xeris has granted an exclusive worldwide license for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab using Xeris’ XeriJect technology in thyroid eye disease (TED) - a serious, progressive and potentially vision-threatening rare autoimmune disease.

Teprotumumab-trbw, known as Tepezza in the USA, was developed and marketed Horizon Therapeutics, the $27.8 billion acquisition of which Amgen completed last year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology